Immunoadoptive Cell Therapy Profile
Key Indicators
- Authorised Capital ₹ 4.90 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 1024.01%
- Profit Growth -1817.60%
- Ebitda -1213.97%
- Net Worth 10295.34%
- Total Assets 8931.73%
About Immunoadoptive Cell Therapy
Immunoadoptive Cell Therapy Private Limited (ICTPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 08 October 2018 (Six years and four months 17 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.90 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Ravindranath Kancherla, Chava Satyanarayana, Shirish Arya, and Three other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999MH2018PTC315497
- Company No.
315497
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 2018
- Date of AGM
24 May 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Immunoadoptive Cell Therapy?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shirish Arya  | Director | 06-Aug-2021 | Current |
| Shalini Purwar | Whole-Time Director | 08-Oct-2018 | Current |
| Ravindranath Kancherla | Nominee Director | 09-Dec-2021 | Current |
| Chava Satyanarayana | Nominee Director | 09-Dec-2021 | Current |
| Rahul Purwar | Director | 08-Oct-2018 | Current |
| Atharva Karulkar | Director | 29-Oct-2021 | Current |
Financial Performance of Immunoadoptive Cell Therapy.
Immunoadoptive Cell Therapy Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1024.01% increase. The company also saw a substantial fall in profitability, with a 1817.6% decrease in profit. The company's net worth Soared by an impressive increase of 10295.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunoadoptive Cell Therapy?
In 2022, Immunoadoptive Cell Therapy had a public holding of 30.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmaceuticals Export Promotion Council Of IndiaChava Satyanarayana is a mutual person
Advy Chemical Private LimitedRahul Purwar is a mutual person
Laurus Bio Private LimitedChava Satyanarayana is a mutual person
Laurus Labs LimitedRavindranath Kancherla and Chava Satyanarayana are mutual person
Chemiasoft Private LimitedChava Satyanarayana is a mutual person
Immunoact Research FoundationShirish Arya, Rahul Purwar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunoadoptive Cell Therapy?
Immunoadoptive Cell Therapy has a workforce of 69 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunoadoptive Cell Therapy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunoadoptive Cell Therapy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
